FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease

Table 1 Baseline patient demographics

Change management	Total	Yes	No	Unsure	Pos FC (> 250 μg/g)	Neg FC (< 250 μg/g)
n	279	143	121	15	81	198
Age	39.4 ± 13.5	38.9	40	40.5
Disease location, n (%)
Crohn's disease	147	56 (38.1)	88 (59.9)	3 (2.0)	55 (37.4)	92 (62.6)
UC	43	17 (39.5)	20 (46.5)	6 (14.0)	20 (46.5)	23 (53.5)
Current Rx
5-ASA	44	16	24	4	18	26
Steroids	23	17	4	2	11	12
Biologics	58	32	24	2	24	34
IMM	63	35	24	4	28	35
None	136	67	61	8	24	112
Indication for FC test
To diagnose IBD	90	40	45	5	7	83
To distinguish IBS from IBD	85	46	37	2	33	52
As an objective measure of disease activity	104	57	39	8	41	63

Patient demographics, indication for the test and the number of subjects with a positive or negative result and the impact on patient management. FC: Fecal calprotectin; UC: Ulcerative colitis; 5-ASA: 5-aminosalycilate; IMM: Immunomodulator; IBD: Inflammatory bowel disease; IBS: Irritable bowel syndrome.